Director Edward Neugeboren of Matinas BioPharma Holdings, Inc. filed an amended ownership statement on November 9, 2026, correcting an administrative error in the reported exercise price of a stock option granted on November 6, 2026.

Key Highlights

  • Amendment purpose: The filing was submitted solely to correct an administrative error in the exercise price of a previously reported stock option in Column 2 of Table II.
  • Corrected exercise price: The stock option exercise price is stated as $1.19 per share.
  • Option grant: Director Neugeboren was granted an option to purchase 5,000 shares of Matinas BioPharma common stock on November 6, 2026.
  • Vesting terms: The option vests in full on the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the plan, subject to continued service.
  • Plan: The option was granted pursuant to the issuer's 2025 Equity Incentive Plan.
  • Beneficial ownership following grant: Neugeboren beneficially owns 5,000 derivative securities (the option) on a direct basis following the reported transaction.

Matinas BioPharma Director Option Grant and Exercise Price Correction

According to the amended filing, Edward Neugeboren, a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), received a stock option on November 6, 2026, to purchase 5,000 shares of the company's common stock, par value $0.0001 per share. The option has an expiration date of November 6, 2036, and carries an exercise price of $1.19 per share. The option was granted under the issuer's 2025 Equity Incentive Plan and was recorded as acquired (transaction code "A") at a price of $0.

The amended filing explains that the original Form 4, also filed on November 6, 2026, contained an administrative error in the reported exercise price in Column 2 of Table II. The amendment was filed on November 9, 2026, solely to correct that error, with no other changes to the previously reported transaction details. Matinas BioPharma is a clinical-stage biopharmaceutical company, and the option grant to Neugeboren is described as being subject to continued service through the applicable vesting date, with vesting accelerated upon a qualifying change in control event as defined by the plan.

The amended form was signed by Jerome D. Jabbour as attorney-in-fact for Edward Neugeboren. Following the reported transaction, Neugeboren holds 5,000 derivative securities in the form of this stock option, owned directly.

What Was Disclosed

Matinas BioPharma director Edward Neugeboren filed an amended ownership statement correcting the exercise price of a 5,000-share stock option granted November 6, 2026, under the company's 2025 Equity Incentive Plan. The corrected exercise price is $1.19 per share, with a ten-year term.